pharmaceutical

Failure-to-warn claims preempted in Texas unless the FDA finds fraud

By Julie Beck | April 30, 2012

5th Circuit decision deepens circuit split on fraud-on-the-FDA statute preemption
Texas’ deal in Risperdal case finalized

By Cathleen Flahardy | March 28, 2012

A judge in Texas has finalized the $158 million settlement Johnson & Johnson (J&J) reached with the state in January over the marketing of its antipsychotic drug Risperdal.
In-house career changes

By Alanna Byrne | March 27, 2012

Notable moves in the corporate legal world
Johnson & Johnson heads back to court in Risperdal suit

By Cathleen Flahardy | March 26, 2012

J&J will head back to a Texas courtroom to further discuss the $158 million settlement it had reached with the state in January.
No deal in Johnson & Johnson Risperdal case

By Cathleen Flahardy | March 12, 2012

Federal prosecutors have rejected a proposed settlement with Johnson & Johnson over the marketing of its drug Risperdal.
7 noteworthy in-house career moves

By Alanna Byrne | February 29, 2012

Charting some of the most recent GC and in-house appointments
Glaxo has right to sell generic Paxil

By Alex Vorro | February 24, 2012

Good news for GlaxoSmithKline Plc. (GSK) U.S. District Judge Joel Pisano ruled yesterday that the pharmaceutical giant has the right to sell an authorized copy of its anti-depressant, Paxil CR, to Canadian pharmaceutical company Apotex Inc.
Teva to pay $250 million to end hepatitis C cases

By Ashley Post | February 21, 2012

One pharmaceutical company recently learned that it shouldn’t exactly embrace the Earth-friendly mantra “reduce, reuse, recycle.”
Novartis pays $99 million in overtime case

By Cathleen Flahardy | January 25, 2012

Novartis AG has agreed to pay $99 million to settle a case that involves 7,000 plaintiffs.
J&J may pay more than $1 billion in Risperdal case

By Cathleen Flahardy | January 6, 2012

According to a Bloomberg report last night, Johnson & Johnson has agreed to pay more than $1 billion to end an investigation into the marketing of its antipsychotic drug Risperdal.